|1.||Reed, Michael J: 2 articles (09/2008 - 02/2003)|
|2.||Purohit, Atul: 2 articles (09/2008 - 02/2003)|
|3.||Potter, Barry V L: 2 articles (09/2008 - 02/2003)|
|4.||Leese, Mathew P: 2 articles (09/2008 - 02/2003)|
|5.||Reed, M J: 2 articles (05/2004 - 09/2003)|
|6.||Potter, B V L: 2 articles (05/2004 - 09/2003)|
|7.||Purohit, A: 2 articles (05/2004 - 09/2003)|
|8.||Leese, M P: 2 articles (05/2004 - 09/2003)|
|9.||Joubert, A M: 1 article (11/2011)|
|10.||Visagie, M H: 1 article (11/2011)|
05/01/2004 - "Our results suggest that 2-MeOE2bisMATE and TRAIL might be a particularly effective combination of anti-cancer agents."
12/01/2010 - "Since 2-MeOE2bisMATE is regarded as a potential anti-cancer agent, it is also imperative to investigate the susceptibility of non-tumorigenic cells to its influence. "
09/01/2003 - "Second generation inhibitors, such as 2-MeOE2bisMATE, which also inhibit the growth of ER- tumours should be active against a wide range of cancers."
02/01/2003 - "The anti-proliferative and STS inhibitory properties of 2-MeOE2bisMATE suggest that it has considerable potential for development as a novel anti-cancer drug."
09/01/2008 - "We have developed a novel, flow cytometry based, ex vivo method which shows in cells recovered from MDA-MB-231 tumors treated with 2-MeOE2bisMATE and 2-EtE2bisMATE an increase in intra-tumoral G(2)-M arrest and apoptosis. "
|3.||Breast Neoplasms (Breast Cancer)
05/01/2004 - "2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases."
09/01/2008 - "2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique."
|1.||Heterologous Transplantation (Xenotransplantation)